Navigation Links
CareFusion Reports Second Quarter Fiscal 2012 Results
Date:2/2/2012

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ -- CareFusion Corp. (NYSE: CFN), a leading, global medical technology company, today reported results for the three and six months ended Dec. 31, 2011.  

"Our second quarter results were led by strong performance across the Medical Systems segment, with our three major businesses achieving positive gains and positioning us well for the second half of the year," said Kieran Gallahue, chairman and CEO. "These results were partially offset by our performance in the Procedural Solutions segment, as we indicated in our preliminary earnings report last month. We continue to believe that our highly differentiated Procedural Solutions products will grow faster than the market and remain meaningful contributors to our long-term performance.

"We continued to make good progress on our efforts to build our foundation and to invest in areas that will help simplify how we do business so we can expand margins and accelerate top-line growth over the long term. We remain committed to our long-term growth targets and are confident we will make progress against these goals this fiscal year."

Second Quarter ResultsThe company reported revenue for the second quarter of fiscal 2012 of $915 million, compared to $886 million in the second quarter of fiscal 2011, an increase of 3 percent on a reported and constant currency basis.

Operating income was $143 million, an increase of 17 percent compared to $122 million in the prior year period. Excluding nonrecurring items, adjusted operating income for the second quarter was unchanged at $150 million.

Operating expenses totaled $314 million in the second quarter. Excluding nonrecurring items, adjusted operating expenses were $307 million, an increase of 4 percent over the prior year period, primarily driven by operating expenses from Rowa Technologies, which the company acquired in August 2011. In addition, the company increased investments in research and development during the quarter and benefited from ongoing cost-savings initiatives in the company's administrative support functions.

The company reported income from continuing operations in the second quarter of $95 million, or $0.42 per diluted share. Adjusted income from continuing operations increased 4 percent from the prior year period to $99 million, or $0.44 per diluted share. The adjusted tax rate was 25.2 percent for the second quarter.

Medical SystemsSecond quarter revenue for the Medical Systems segment increased 9 percent from the prior year period on a reported and constant currency basis to $571 million, driven by strong sales across the segment. The company's Dispensing Technologies business, which grew in part from a contribution from the first-quarter acquisition of Rowa Technologies, also delivered its second strongest first-half organic revenue and committed contract performance in its history. The Infusion Systems business also achieved solid revenue growth, driven by installations of a record number of competitive channels during the quarter.

The revenue growth resulted in higher segment profit for the quarter, which increased 27 percent from the prior year period to $121 million. Adjusted segment profit increased 12 percent from the prior year period to $124 million.

Procedural SolutionsSecond quarter revenue for the Procedural Solutions segment decreased 5 percent from the prior year period on a reported and constant currency basis. The decrease was driven, in part, by the loss of sales from divesting the company's OnSite Services business in March 2011. Net of the OnSite Services business divestiture, segment revenues decreased 2 percent from the prior year period. The segment results were also affected by decreased sales of respiratory disposables products in the Specialty Disposables business.

The revenue decline led to a decrease in segment profit of 19 percent from the prior year period to $22 million, and adjusted segment profit decreased 33 percent to $26 million.  

Six-Month ResultsFor the first six months of fiscal 2012, revenue increased 4 percent from the prior year period to $1.76 billion. Operating income increased to $251 million from $201 million in the prior year period. Income from continuing operations was $162 million, or $0.72 per diluted share. Adjusted income from continuing operations increased 10 percent from the prior year period to $175 million, or $0.78 per diluted share.

Operating expenses in the first six months totaled $633 million, or $615 million on an adjusted basis.  

Segment results for the six months ended Dec. 31, 2011 and 2010 are as follows:Medical Systems1H FY121H FY11Y/YRevenue

$1,080 million

$991 million

9%Segment Profit

$209 million

$163 million

28%Adjusted Segment Profit

$219 million

$201 million

9%Procedural Solutions1H FY121H FY11Y/YRevenue

$679 million

$706 million

(4)%Segment Profit

$42 million

$38 million

11%Adjusted Segment Profit

$50 million

$67 million

(25)%Additional second quarter and recent highlights included:

  • Launching the Pyxis® Enterprise System (ES) platform, the next generation of CareFusion's industry-leading automated dispensing systems that will enable hospital customers to simplify and standardize the medication management process, both within a single facility and across an entire health system. Notable product releases on the platform are the Pyxis Enterprise Server, Pyxis MedStation® ES and CareFusion Coordination Engine.
  • Launching the CareFusion Ventilation System, combining CareFusion's industry-leading ventilators with new interoperability and analytics software to better address clinical and operational challenges in patient care.
  • Receiving federal data encryption certification for the Alaris® System, becoming the first and only infusion system to receive the National Institute of Standards and Technology certification now required for infusion devices operating on the U.S. Department of Veterans Affairs' hospital networks.
  • Earning top rankings from KLAS, an independent market research firm that awarded MedMined® Services the No. 1 ranking in its 2011 annual report on infection control and monitoring providers, and from MD Buyline, which recognized Pyxis® technologies as number one in user satisfaction ratings in its December 2011 quarterly report.
  • Launching the Nicolet™ EEG (Electroencephalography) Wireless Amplifier, a device that effectively captures high-resolution brain wave data to be used with the Nicolet Neurodiagnostic system.

  • Fiscal 2012 OutlookCareFusion continues to expect full-year consolidated revenue to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. The company narrowed its previous full-year guidance range for adjusted diluted EPS from continuing operations of $1.75 to $1.90 to a new range of $1.75 to $1.85.

    The guidance is based on an assumed diluted weighted average outstanding share count of approximately 227 million.

    Conference CallCareFusion will host a conference call today at 2 p.m. PST (5 p.m. EST) to discuss earnings results for the second quarter fiscal 2012.

    To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

    Investors and other interested parties may also access the call by dialing (800) 901-5247 within the U.S. or (617) 786-4501 from outside the U.S., and use the access code 28588340. A replay of the conference call will be available from 5 p.m. PST (8 p.m. EST) on Feb. 2 through 8:59 p.m. PST (11:59 p.m. EST) on Feb. 9 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 internationally and using the access code 19918894.

    About CareFusion CorporationCareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

    ###Use of Non-GAAP Financial Measures by CareFusion Corporation This CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows: "adjusted operating expenses" and "adjusted operating income", which exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges; "adjusted income from continuing operations", "adjusted diluted earnings per share from continuing operations" and "adjusted tax rate", which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items; and "adjusted segment profit", which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

    The most directly comparable measure for these non-GAAP financial measures are operating expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarters and six months ended Dec. 31, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

    In addition, CareFusion presents the non-GAAP financial measure "adjusted income from continuing operations per diluted share" on a forward-looking basis. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Feb. 2, 2012.

    Cautions Concerning Forward-looking StatementsThe CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Feb. 2, 2012. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.CAREFUSION CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME(UNAUDITED)Quarter Ended Six Months Ended December 31,December 31,(in millions, except per share amounts)2011201020112010Revenue

    $

    915

    $

    886

    $

    1,759

    $

    1,697Cost of Products Sold458441875839Gross Margin457445884858Selling, General and Administrative Expenses267270540542Research and Development Expenses40367976Restructuring and Acquisition Integration Charges7171439Operating Income143122251201Interest Expense and Other, Net 17204243Income Before Income Tax126102209158Provision for Income Tax31294749Income from Continuing Operations9573162109Income from Discontinued Operations, Net of Tax-3-5Net Income

    $

    95

    $

    76

    $

    162

    $

    114Per Share Amounts: (1)Basic Earnings per Common Share:Continuing Operations

    $

    0.42

    $

    0.32

    $

    0.72

    $

    0.49Discontinued Operations

    $

    -

    $

    0.01

    $

    -

    $

    0.02Basic Earnings per Common Share

    $

    0.42

    $

    0.34

    $

    0.72

    $

    0.51Diluted Earnings per Common Share:Continuing Operations

    $

    0.42

    $

    0.32

    $

    0.72

    $

    0.49Discontinued Operations

    $

    -

    $

    0.01

    $

    -

    $

    0.02Diluted Earnings per Common Share

    $

    0.42

    $

    0.34

    $

    0.72

    $

    0.51Weighted-Average Number of Common Shares Outstanding:Basic224.7222.8224.3222.4Diluted226.6224.5226.5224.2(1)Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended December 31, 2011Nonrecurring(in millions, except per share amounts)GAAPItems (1)Adjusted (2)Revenue (3)$

    915

    $

    -

    $

    915Cost of Products Sold458-458Gross Margin457-457Selling, General and Administrative Expenses267-267Research and Development Expenses40-40Restructuring and Acquisition Integration Charges 7(7)-Operating Income1437150Interest Expense and Other, Net 17-17Income Before Income Tax1267133Provision for Income Tax31334Net Income $

    95

    $

    4

    $

    99Per Share Amounts: (4)Basic Earnings per Common Share$

    0.42

    $

    0.02

    $

    0.44Diluted Earnings per Common Share$

    0.42

    $

    0.02

    $

    0.44Weighted-Average Number of Common Shares Outstanding:Basic224.7224.7224.7Diluted 226.6226.6226.6Effective Tax Rate (5)24.7%27.0%25.2%____________(1)Reflects nonrecurring charges primarily related to restructuring.  (2)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(3)Revenues increased $29 million or 3% for the quarter ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is also 3%.(4)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. (5)Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Six Months Ended December 31, 2011Nonrecurring(in millions, except per share amounts)GAAPItems (1)Adjusted (2)Revenue (3)$

    1,759

    $

    -

    $

    1,759Cost of Products Sold875-875Gross Margin884-884Selling, General and Administrative Expenses540(4)536Research and Development Expenses79-79Restructuring and Acquisition Integration Charges 14(14)-Operating Income25118269Interest Expense and Other, Net 42-42Income Before Income Tax20918227Provision for Income Tax47552Net Income $

    162

    $

    13

    $

    175Per Share Amounts: (4)Basic Earnings per Common Share$

    0.72

    $

    0.06

    $

    0.78Diluted Earnings per Common Share$

    0.72

    $

    0.06

    $

    0.78Weighted-Average Number of Common Shares Outstanding:Basic224.3224.3224.3Diluted 226.5226.5226.5Effective Tax Rate (5)22.5%26.1%22.7%____________(1)Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff.  (2)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(3)Revenues increased $62 million or 4% for the six months ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is 3%.(4)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. (5)Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Quarter Ended December 31, 2010DiscontinuedNonrecurring(in millions, except per share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue$

    886

    $

    -

    $

    -

    $

    886Cost of Products Sold441--441Gross Margin445--445Selling, General and Administrative Expenses270-(11)259Research and Development Expenses36--36Restructuring and Acquisition Integration Charges 17-(17)-Operating Income122-28150Interest Expense and Other, Net 20--20Income Before Income Tax102-28130Provision for Income Tax29-635Income from Continuing Operations73-2295Income from Discontinued Operations, Net of Tax3(3)---Net Income

    $

    76

    $

    (3)

    $

    22

    $

    95Per Share Amounts: (4)Basic Earnings per Common Share

    $

    0.34

    $

    (0.01)

    $

    0.10

    $

    0.42Diluted Earnings per Common Share

    $

    0.34

    $

    (0.01)

    $

    0.10

    $

    0.42Weighted-Average Number of Common Shares Outstanding:Basic222.8222.8222.8222.8Diluted 224.5224.5224.5224.5Effective Tax Rate (5)28.8%n/a20.3%26.9%____________(1)Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations. (2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  (3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. (5)Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above. CAREFUSION CORPORATIONADJUSTED FINANCIAL INFORMATION(UNAUDITED)Six Months Ended December 31, 2010DiscontinuedNonrecurring(in millions, except per share amounts)GAAP Operations (1)Items (2)Adjusted (3)Revenue$

    1,697

    $

    -

    $

    -

    $

    1,697Cost of Products Sold839--839Gross Margin858--858Selling, General and Administrative Expenses542-(28)514Research and Development Expenses76--76Restructuring and Acquisition Integration Charges 39-(39)-Operating Income201-67268Interest Expense and Other, Net 43--43Income Before Income Tax158-67225Provision for Income Tax49-1766Income from Continuing Operations109-50159Income from Discontinued Operations, Net of Tax5(5)--Net Income

    $

    114

    $

    (5)

    $

    50

    $

    159Per Share Amounts: (4)Basic Earnings per Common Share

    $

    0.51

    $

    (0.02)

    $

    0.23

    $

    0.72Diluted Earnings per Common Share

    $

    0.51

    $

    (0.02)

    $

    0.22

    $

    0.71Weighted-Average Number of Common Shares Outstanding:Basic222.4222.4222.4222.4Diluted224.2224.2224.2224.2Effective Tax Rate (5)30.8%n/a24.7%29.0%____________(1)Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations. (2)Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  (3)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.(4)Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented. (5)Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above. CAREFUSION CORPORATIONADJUSTED SEGMENT FINANCIAL INFORMATION(UNAUDITED)Quarter Ended December 31, 2011Nonrecurring(in millions)GAAP Items (1)Adjusted (2)Medical SystemsRevenue$

    571

    $

    -

    $

    571Segment Profit$

    121

    $

    3

    $

    124Procedural SolutionsRevenue$

    344

    $

    -

    $

    344Segment Profit$

    22

    $

    4

    $

    26Six Months Ended December 31, 2011Nonrecurring(in millions)GAAP Items (3)Adjusted (2)Medical SystemsRevenue$

    1,080

    $

    -

    $

    1,080Segment Profit$

    209

    $

    10

    $

    219Procedural SolutionsRevenue$

    679

    $

    -

    $

    679Segment Profit$

    42

    $

    8

    $

    50Quarter Ended December 31, 2010Nonrecurring(in millions)GAAP Items (4)Adjusted (2)Medical SystemsRevenue$

    523

    $

    -

    $

    523Segment Profit$

    95

    $

    16

    $

    111Procedural SolutionsRevenue$

    363

    $

    -

    $

    363Segment Profit$

    27

    $

    12

    $

    39Six Months Ended December 31, 2010Nonrecurring(in millions)GAAP Items (4)Adjusted (2)Medical SystemsRevenue$

    991

    $

    -

    $

    991Segment Profit$

    163

    $

    38

    $

    201Procedural SolutionsRevenue$

    706

    $

    -

    $

    706Segment Profit$

    38

    $

    29

    $

    67____________(1)Reflects nonrecurring charges primarily related to restructuring.  (2)Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted. (3)Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff. (4)Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.CAREFUSION CORPORATIONSEGMENT AND SELECT BUSINESS LINE REVENUES(UNAUDITED)Quarter EndedSix Months EndedDecember 31,December 31,(in millions)20112010 (1)PercentChange20112010 (1)PercentChangeMedical SystemsDispensing Technologies

    $

    257

    $

    229

    12%$

    494

    $

    434

    14%Infusion Systems239223

    7445415

    7Respiratory Technologies6965

    6129130

    (1)Other66

    -1212

    -Total Medical Systems

    $

    571

    $

    523

    9$

    1,080

    $

    991

    9Procedural SolutionsInfection Prevention

    $

    142

    $

    142

    -%$

    280

    $

    277

    1%Medical Specialties7978

    1157156

    1Specialty Disposables6573

    (11)131143

    (8)Other5870

    (17)111130

    (15)Total Procedural Solutions

    $

    344

    $

    363

    (5)$

    679

    $

    706

    (4)Total CareFusion$

    915

    $

    886

    3%$

    1,759

    $

    1,697

    4%____________(1)Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the International Surgical Products (ISP) business. The ISP business was divested in April 2011, and has been classified as discontinued operations. (Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)


    '/>"/>

    SOURCE CareFusion Corp.
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. CareFusion Provides Update on Voluntary Recall of Neurological Monitoring Software and Devices
    2. CareFusion Receives Federal Data Encryption Certification for Alaris® Infusion System
    3. CareFusion Announces Preliminary Second Quarter Results
    4. CareFusion Provides Update on Previously Announced Ventilator Recall
    5. CareFusion Showcases Medication Management Technologies at American Society for Health-System Pharmacists Conference
    6. CareFusion Launches Wireless Diagnostic and Monitoring Neurological Device
    7. CareFusion Announces New Ventilation Solution to Help Hospitals Provide Improved Patient Care and Reduce Costs
    8. CareFusion Initiates Class I Recall of EnVe Ventilators
    9. CareFusion Launches New Emergency Transport Ventilator
    10. B. Braun Medical Sues CareFusion for Patent Infringement
    11. CareFusion Reports Fourth Quarter and Fiscal 2011 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
    (Date:2/5/2016)... 2016 --> ... that the global active pharmaceuticals ingredients (APIs) market stood ... reach US$185.9 bn by 2020. It is expected to ... 2020. The title of the report is "Active Pharmaceutical ... and by Therapeutic Area) - Global Industry Analysis, Size, ...
    (Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Regular gym ... find themselves having to wait longer to access the treadmills. It’s a predictable trend. ... resolutions to lose weight and get in shape by joining gyms, starting new walking ...
    (Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
    (Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
    (Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers ... the start of Project HoldSpace. Through the partnership, the two organizations seek to ... youth between the ages of 13 and 18. Currently focused on Ohio schools, ...
    Breaking Medicine News(10 mins):